BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $BNTX readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07798648-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:BNT162b2 readout (P3) · BioNTech SE $BNTX
DESCRIPTION:A Study of COVID-19 Vaccine(s) in Children and Adults\n\nPrimar
 y completion date: 2027-04-12 (estimated)\nPhase 3 · Infectious · COVID-
 19 Vaccines\nEnrollment: 713 · Sites: 15\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07798648\nhttps://
 clinicaltrials.gov/study/NCT07798648
URL:https://datacutoff.com/radar.html?nct=NCT07798648
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449209-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~BNT327 Dose Level 1 (DL1) readout (P2) · BioNTech SE $BNTX
DESCRIPTION:Safety\, Preliminary Effectiveness of BNT327\, an Investigation
 al Therapy for Patients With Small-cell Lung Cancer in Combination With Ch
 emotherapy\n\nPrimary completion date: 2027-06 (estimated) — month only\
 , shown on the 1st\nOriginally planned: 2025-02 (+27.9 months)\nPhase 2 ·
  Oncology · Extensive-stage Small-cell Lung Cancer\, Small-cell Lung Canc
 er\nEnrollment: 110 · Sites: 64\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT06449209\nhttps://clinicalt
 rials.gov/study/NCT06449209
URL:https://datacutoff.com/radar.html?nct=NCT06449209
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379580-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~BNT166a readout (P2) · BioNTech SE $BNTX
DESCRIPTION:A Randomized Clinical Trial Investigating the Safety\, Reactoge
 nicity\, and Immunogenicity After Immunization With an mRNA-based Mpox Vac
 cine Candidate in Africa\n\nPrimary completion date: 2027-06 (estimated) 
 — month only\, shown on the 1st\nPhase 2 · Infectious · Mpox (Monkeypo
 x)\, Smallpox\, Orthopoxvirus Infection\nEnrollment: 310 · Sites: 6\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.htm
 l?nct=NCT07379580\nhttps://clinicaltrials.gov/study/NCT07379580
URL:https://datacutoff.com/radar.html?nct=NCT07379580
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
